Calamos Advisors’s Hologic HOLX Stock Holding History

Calamos Advisors’s Portfolio HOLX Stock Details HOLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-345,114	Closed	-$12.7M	–	618
2017 Q3	$12.7M	Sell	345,114 -4,631	-1%	-$187K	0.1%	244
2017 Q2	$15.9M	Sell	349,745 -150,159	-30%	-$6.63M	0.12%	231
2017 Q1	$21.3M	Sell	499,904 -23,000	-4%	-$938K	0.17%	179
2016 Q4	$21M	Buy	+522,904	New	+$20.2M	0.17%	173

Other funds holding HOLX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Calamos Advisors's HOLX Position: Q4 2017 in Review

Calamos Advisors sold out of Hologic (HOLX) in Q4 2017, closing a stake of 345,114 shares — an estimated $12.7M sold.

Calamos Advisors first reported a position in HOLX in Q4 2016 and held it in 4 quarters. The position peaked at $21.3M in Q1 2017. 472 funds tracked by Wall St. Rank hold HOLX as of Q4 2017.

Calamos Advisors reported no remaining Hologic position as of Q4 2017 after selling out during the quarter.
Calamos Advisors sold 345,114 Hologic shares in Q4 2017, an estimated $12.7M.
Calamos Advisors first reported a position in Hologic in Q4 2016 and held it in 4 quarters.
Calamos Advisors's Hologic position peaked at $21.3M in Q1 2017.
472 funds tracked by Wall St. Rank held Hologic as of Q4 2017.

Based on Calamos Advisors's 13F filing for Q4 2017, filed 13 Feb 2018.